Literature DB >> 11727205

[A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia].

J Pérez Nellar1, A M Domínguez, J A Llorens-Figueroa, A Ferrá-Betancourt, A Pardo, M Quiala, Z Gali.   

Abstract

INTRODUCTION: Thymectomy is a well established procedure in myasthenia gravis (MG). To reduce its morbidity, treatments which are effective in the short term, such as plasmapheresis and intravenous immunoglobulin (IGI) have been used.
OBJECTIVE: To evaluate the efficacy and tolerability of the IGI, compared with plasmapheresis, in the preparation of myasthenic patients before thymectomy. PATIENTS AND METHODS: We compared a group of 33 prospective myasthenic patients treated with IGI with 38 clinical histories taken as controls treated by plasmapheresis during the peri operative period of thymectomy.
RESULTS: The patients treated with IGI were in the intensive care unit and neurology ward for less time. The endotracheal tube was also removed sooner. However, these differences were not significant. The commonest complications of IGI were fever, shivering and phlebitis. The most frequent adverse reaction to plasmapheresis were cutaneous eruptions. One patient developed Hepatitis C after plasmapheresis.
CONCLUSION: IGI is comparable in efficacy to plasmapheresis in the peri operative period of MG, but has a better profile of adverse reactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11727205

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  5 in total

Review 1.  IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.

Authors:  Isabel Illa
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

Review 2.  Intravenous immunoglobulin for myasthenia gravis.

Authors:  Philippe Gajdos; Sylvie Chevret; Klaus V Toyka
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

3.  Current and emerging treatments for the management of myasthenia gravis.

Authors:  Sivakumar Sathasivam
Journal:  Ther Clin Risk Manag       Date:  2011-07-22       Impact factor: 2.423

4.  Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis.

Authors:  Josep Gamez; María Salvadó; Francesc Carmona; Miriam de Nadal; Laura Romero; Daniel Ruiz; Alberto Jáuregui; Olga Martínez; Javier Pérez; Pilar Suñé; María Deu
Journal:  Ther Adv Neurol Disord       Date:  2019-07-17       Impact factor: 6.570

Review 5.  Plasma exchange for myasthenia gravis.

Authors:  P Gajdos; S Chevret; K Toyka
Journal:  Cochrane Database Syst Rev       Date:  2002
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.